Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for a combination therapy involving its adebrelimab (SHR-1316) with Hansoh Pharmaceutical Group Co., Ltd’s (HKG: 3692) Ameile (almonertinib) or SHR-A2009, with or without chemotherapy, for the treatment of advanced solid tumors.
Adebrelimab: A PD-L1 Monoclonal Antibody for Cancer Treatment
Adebrelimab, a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb), was approved in China in March this year for the treatment of first-line extensive stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy. This approval marks a significant advancement in the treatment options for patients with ES-SCLC.
SHR-A2009: An Innovative Antibody-Drug Conjugate (ADC)
SHR-A2009 is an in-house developed antibody-drug conjugate (ADC) that targets tumor-specific antigens. The mechanism of action involves the drug being endocytosed into the cells by binding to the target antigen on the surface of tumor cells, followed by the release of small-molecule toxins to kill the tumor cells. This innovative approach offers a targeted treatment option for patients with advanced solid tumors.-Fineline Info & Tech
